Immune modulation in cancer with antibodies - Book review Journal Article


Authors: Page, D. B.; Postow, M. A.; Callahan, M. K.; Allison, J. P.; Wolchok, J. D.
Article Title: Immune modulation in cancer with antibodies - Book review
Abstract: Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011 for advanced melanoma on the basis of survival benefit. Since that time, we have made significant strides in optimizing this therapy: we have characterized the spectrum of immune-related adverse events and learned how to mitigate them with treatment algorithms, discovered potential biomarkers of activity, and identified the potential synergy between checkpoint modulation and other therapeutic modalities. Recent phase I trials have established the efficacy and safety of next-generation checkpoint agents, including PD-1 and PD- L1 inhibitors, across multiple tumor types. Much work lies ahead in developing these next- generation checkpoint agents, testing them in combination, and determining how to integrate them into the treatment paradigms of various tumor types.
Keywords: ipilimumab; immunotherapy; ctla-4; phase-ii trial; metastatic melanoma; monoclonal-antibody; blockade; tremelimumab; anti-ctla-4; dose-escalation trial; resistant prostate-cancer; open-label; t-cell tolerance; nivolumab; anti-pd-1 antibody; anti-pd-1; advanced melanoma patients; anti-pd-l1; mk-3475
Journal Title: Annual Review of Medicine
Volume: 65
ISSN: 0066-4219
Publisher: Annual Reviews  
Date Published: 2014-01-01
Start Page: 185
End Page: 202
Language: English
ACCESSION: WOS:000336053000013
DOI: 10.1146/annurev-med-092012-112807
PROVIDER: wos
PUBMED: 24188664
Notes: Review; Book Chapter -- 978-0-8243-0565-9 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Michael Andrew Postow
    362 Postow
  3. Margaret Kathleen Callahan
    197 Callahan
  4. David B Page
    30 Page